US4407795A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Inclusion compound of p-hexadecylamino benzoic acid in cyclodextrin and method of use
Assignee: Wyeth Holdings LLC
•
Filing: 1981-07-16
•
Granted: 1983-10-04
•
Expires: 2001-07-16
Abstract
Abstract An inclusion compound of p-hexadecylamino benzoic acid sodium salt in β-cyclodextrin which provides enhanced bioavailability of this antiatherosclerotic agent.
Inventors
- 👤 Gabriela Nicolau
- 👤 Alfred P. Tonelli
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 19:03
CPC Classifications
B; B82; B82Y; B82Y5/00; A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K31/195; A61K47/00; A61K47/50; A61K47/69; A61K47/6949; A61K47/6951; A61P; A61P9/00; A61P9/10; C; C08; C08B; C08B37/00; C08B37/0006; C08B37/0009; C08B37/0012; C08B37/0015
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
61 words
The method of inhibiting atherosclerotic occlusion of the arteries in a mammal which comprises orally administering to said mammal an effective amount of an inclusion compound comprising about 8% p-hexadecylamino benzoic acid sodium salt in β-cyclodextrin in a molar ratio of about 1:4 of said salt to β-cyclodextrin which provides enhanced bioavailability of said salt over said salt orally administered alone.
Claim 2
Independent Claim
61 words
The method of inhibiting atherosclerotic occlusion of the arteries in a mammal which comprises orally administering to said mammal an effective amount of an inclusion compound comprising about 8% p-hexadecylamino benzoic acid sodium salt in β-cyclodextrin in a molar ratio of about 1:4 of said salt to β-cyclodextrin which provides enhanced bioavailability of said salt over said salt orally administered alone.
Claim 3
Dependent Claim
81 words
A composition of matter in oral unit dosage form which provides enhanced bioavailability of p-hexadecylamino benzoic acid sodium salt over said salt alone for inhibiting atherosclerotic occlusion of the arteries in a mammal comprising an inclusion compound of about 8% p-hexadecylamino benzoic acid sodium salt in β-cyclodextrin in a molar ratio of about 1:4 of said salt to β-cyclodextrin containing about 2 to 200 milligrams of said salt in each oral unit dosage form in association with a pharmaceutically acceptable carrier.
Claim 4
Dependent Claim
81 words
A composition of matter in oral unit dosage form which provides enhanced bioavailability of p-hexadecylamino benzoic acid sodium salt over said salt alone for inhibiting atherosclerotic occlusion of the arteries in a mammal comprising an inclusion compound of about 8% p-hexadecylamino benzoic acid sodium salt in β-cyclodextrin in a molar ratio of about 1:4 of said salt to β-cyclodextrin containing about 2 to 200 milligrams of said salt in each oral unit dosage form in association with a pharmaceutically acceptable carrier.
Claim 5
Dependent Claim
36 words
The inclusion compound of about 8% p-hexadecylamino benzoic acid sodium salt in β-cyclodextrin in a molar ratio of about 1:4 of said salt to β-cyclodextrin which provides enhanced bioavailability of said salt over said salt alone.
Claim 6
Dependent Claim
36 words
The inclusion compound of about 8% p-hexadecylamino benzoic acid sodium salt in β-cyclodextrin in a molar ratio of about 1:4 of said salt to β-cyclodextrin which provides enhanced bioavailability of said salt over said salt alone.
References Cited (Backward Citations)
US3472835A
Cited
US3453257A
Cited
US3453260A
Cited
US3459732A
Cited
US4066829A
Cited
US4100342A
Cited
US4311694A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-10-03 | 1987-04-04 | 1987-10-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-10-03 | 1991-04-04 | 1991-10-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-10-03 | 1995-04-04 | 1995-10-04 | $7700.00 | Window Closed / Lapsed |